<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="950">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148780</url>
  </required_header>
  <id_info>
    <org_study_id>CR109104</org_study_id>
    <secondary_id>NOPRODRSV4002</secondary_id>
    <nct_id>NCT05148780</nct_id>
  </id_info>
  <brief_title>A Study of Acute Respiratory Infections in Global Outpatient Setting</brief_title>
  <acronym>ARGOS</acronym>
  <official_title>Acute Respiratory Infections Global Outpatient Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the positivity rate of respiratory syncytial virus&#xD;
      (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in&#xD;
      high-risk participants presenting with acute respiratory infections (ARIs) in outpatient&#xD;
      settings during the influenza/RSV season and to evaluate the association between lower&#xD;
      respiratory tract disease (LRTD) and ARI-related hospitalization in participants positive for&#xD;
      RSV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower respiratory tract infections (LRTIs) are a major cause of mortality and morbidity&#xD;
      worldwide with 2.3 million deaths in 2016 alone among all age groups, making it the sixth&#xD;
      leading cause of mortality. The current study aims to assess the burden of RSV infections&#xD;
      among adult participants presenting in outpatient settings, who are at high risk of&#xD;
      complications or progression to severe disease due to their age or pre-existing&#xD;
      comorbidities. Regional data from the United States (US), Europe, Middle East, and Asia&#xD;
      (EMEA) and Asia-Pacific (APAC) will provide evidence on local RSV morbidity, mortality,&#xD;
      medical resource utilization (MRU), standard of care, and quality of life in adults&#xD;
      participants. A subset of participants positive for influenza virus and/or SARS-CoV-2 will&#xD;
      also be enrolled, to allow for a comparative assessment of disease burden between the 3 viral&#xD;
      respiratory pathogens. No study drug will be involved in this study. The total duration of&#xD;
      the study for each participant will be a maximum of 3 months (+-1 week) from the date of&#xD;
      enrollment. Safety will be assessed in the form of adverse events and serious adverse events&#xD;
      related to study devices or procedures and for deaths regardless of causality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Positive for Respiratory Syncytial Virus (RSV)</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants positive for RSV, among those screened for viral pathogens using a polymerase chain reaction (PCR)-based test will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Positive for Influenza Virus</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants positive for influenza virus, among those screened for viral pathogens using a PCR-based test will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants positive for SARS-CoV-2, among those screened for viral pathogens using a PCR- based test will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Relative Risk of Acute Respiratory Infections (ARI)- related Hospitalization in Participants Positive for RSV with Lower Respiratory Tract Disease (LRTD) or Without LRTD</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Number of participants with relative risk of ARI-related hospitalization in participants positive for RSV with LRTD or without LRTD will be reported. LRTD is defined as new onset or worsening from chronic condition of 3 or more of the below symptoms as captured in the Respiratory Infection Intensity and Impact Questionnaire (RiiQTM) V2 at the same assessment time-point: Cough, Short of breath, Coughing up phlegm (sputum), Wheezing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Relative Risk of ARI-related Hospitalization in Participants Positive for Influenza Virus Diagnosed with or Without LRTD</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Number of participants with relative risk of ARI-related hospitalization in participants positive for influenza virus diagnosed with or without LRTD will be reported. LRTD is defined as new onset or worsening from chronic condition of 3 or more of the below symptoms as captured in the RiiQTM V2 at the same assessment time-point: Cough, Short of breath, Coughing up phlegm (sputum), Wheezing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Relative Risk of ARI-related Hospitalization in Participants Positive for SARS-CoV-2 with or Without LRTD</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Number of participants with relative risk of ARI-related hospitalization in participants positive for SARS-CoV-2 with or without LRTD will be reported. LRTD is defined as new onset or worsening from chronic condition of 3 or more of the below symptoms as captured in the RiiQTM V2 at the same assessment time-point: Cough, Short of breath, Coughing up phlegm (sputum), Wheezing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Positive for RSV Reporting ARI-related Hospitalizations During the Study Period</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Percentage of participants positive for RSV reporting ARI-related hospitalizations during the study period will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Positive for Influenza Virus Reporting ARI-related Hospitalizations During the Study Period</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Percentage of participants positive for influenza virus reporting ARI-related hospitalizations during the study period will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Positive for SARS-CoV-2 Reporting ARI-related Hospitalizations During the Study Period</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Percentage of participants positive for SARS-CoV-2 reporting ARI-related hospitalizations during the study period will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI- related Hospitalization in Participants Positive for RSV</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI- related hospitalization in participants positive for RSV will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI- related Hospitalization in Participants Positive for Influenza Virus</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI- related hospitalization in participants positive for influenza virus will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI- related Hospitalization in Participants Positive for SARS-CoV-2</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI- related hospitalization in participants positive for SARS-CoV-2 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Presenting with Complications at Screening and Diagnosed with or Without LRTD</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants presenting with complications at screening and diagnosed with or without LRTD will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting ARI- related Complications During the Follow-up Period and Diagnosed with or Without LRTD</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Percentage of participants reporting ARI- related complications during the follow-up period and diagnosed with or without LRTD will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI- related Complications During the Follow-up Period in Participants Positive for RSV</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI- related complications during the follow-up period in participants positive for RSV will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI- related Complications During the Follow-up Period in Participants Positive for Influenza Virus</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI- related complications during the follow-up period in participants positive for influenza virus will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI- related Complications During the Follow-up Period in Participants Positive for SARS-CoV-2</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI- related complications during the follow-up period in participants positive for SARS-CoV-2 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Presenting with Clinically Relevant Disease at Screening and Diagnosed with or Without LRTD</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants presenting with clinically relevant disease at screening and diagnosed with or without LRTD will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting ARI- related Clinically Relevant Disease During the Follow-up Period and Diagnosed with or Without LRTD</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Percentage of participants reporting ARI-related clinically relevant disease during the follow-up period and diagnosed with or without LRTD will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for RSV</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI-related clinically relevant disease during the follow-up period in participants positive for RSV will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for Influenza Virus</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI-related clinically relevant disease during the follow-up period in participants positive for influenza virus will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for SARS-CoV-2</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Time to ARI-related clinically relevant disease during the follow-up period in participants positive for SARS-CoV-2 will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2960</enrollment>
  <condition>Acute Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Participants with Acute Respiratory Infections (ARI) in Outpatient Setting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants presenting with ARIs in an outpatient setting who are at high risk of progressing to severe disease will be screened for viral respiratory pathogens (respiratory syncytial virus [RSV], Influenza, severe acute respiratory syndrome coronavirus 2 [SARS-COV-2]) by collecting a nasal swab. If a participant is positive for RSV and/or influenza virus and/or SARS-CoV-2 based on a study test or standard-of-care (SOC) polymerase chain reaction (PCR)-based test, the participant will be eligible for enrollment in the study in the home-based short-term and long-term follow-up phases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasal Swab Sample</intervention_name>
    <description>Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.</description>
    <arm_group_label>Participants with Acute Respiratory Infections (ARI) in Outpatient Setting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Present to the general physician (GP)/specialist outpatient settings/respiratory&#xD;
             clinics or in Emergency department (ED) settings with symptoms suggestive of a&#xD;
             diagnosis of Acute Respiratory Infections (ARI)&#xD;
&#xD;
          -  For inclusion in the home-based follow-up phases, must test positive for respiratory&#xD;
             syncytial virus (RSV) and/or influenza and/or Severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) per a molecular-based diagnostic assay (polymerase chain&#xD;
             reaction [PCR]-based) using a nasal swab (nasopharyngeal or similar) sample.&#xD;
             Co-infections are permitted to be enrolled in the study&#xD;
&#xD;
          -  Must be able to read, understand, and complete questionnaires&#xD;
&#xD;
          -  Must be willing to provide verifiable identification, has means to be contacted and to&#xD;
             contact the investigator during the study&#xD;
&#xD;
          -  Willing and able to adhere to the specifications in this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a clinical condition other than those as specified in study protocol which, in the&#xD;
             opinion of the investigator, could prevent, confound, or limit the protocol-specified&#xD;
             assessments&#xD;
&#xD;
          -  Received an investigational drug (including investigational vaccines) within 3 months&#xD;
             before the start of the study or the first data collection time-point&#xD;
&#xD;
          -  Is currently enrolled or plans to participate in another investigational study on RSV,&#xD;
             influenza or SARS-CoV-2 during the current study&#xD;
&#xD;
          -  Is, in the opinion of the investigator, unlikely to adhere to the requirements of the&#xD;
             study, or is unlikely to complete the full course of observation&#xD;
&#xD;
          -  Cannot communicate reliably with the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lakeview Clinical Research</name>
      <address>
        <city>Guntersville</city>
        <state>Alabama</state>
        <zip>35976</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisburg Family Medical Center</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ark Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida, Incorporated</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Snake River Research, PLLC</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kernodle Clinic</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DayStar Clinical Research, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascension Medical Group - St. John Clinic Infectious Disease</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Family Physicians</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Family Medicine Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Clinical Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1119</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital J. M. Ramos Mejía</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <zip>C1221Adc</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico DAMIC</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Platense</name>
      <address>
        <city>La Plata</city>
        <zip>B1900Avg</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica del Niño y la familia</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico de La Fundacion Estudios Clinicos</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico S.A.</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Del Buen Aire</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Mederi de Pesquisa e Saude</name>
      <address>
        <city>Passo Fundo</city>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTA Clinical Research Inc.</name>
      <address>
        <city>Edmonton</city>
        <zip>T5A 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Funcentra</name>
      <address>
        <city>Monteria, Cordoba</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berliner Centrum f. Reise- und Tropenmedizin (BCRT)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>medicoKIT GmbH</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Wallerfing</city>
        <zip>94574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino IRCCS</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale N. 2 Savonese - Presidio ospedaliero di Albenga - Ospedale Santa Corona</name>
      <address>
        <city>Pietra Ligure</city>
        <zip>17027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagikoseikyokai Saka General Hospital</name>
      <address>
        <city>Shiogama</city>
        <zip>985-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan-si</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Putrajaya Presint 9</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Kuang</name>
      <address>
        <city>Kuang</city>
        <zip>48050</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Masjid Tanah</name>
      <address>
        <city>Masjid Tanah</city>
        <zip>78300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miri</name>
      <address>
        <city>Miri</city>
        <zip>98000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Clínica Gramel S.C.</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>3720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Medico Biologica y Terapia Avanzada CIMBYTA</name>
      <address>
        <city>Guadalajara</city>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization S.C.</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Proyectos Clínicos de Oriente UPCO</name>
      <address>
        <city>Valladolid</city>
        <zip>CP97780</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURO-MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Innowacyjnych Terapii Sp. z o.o.</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Pulmonologii i Diagnostyki Chorob Alergicznych</name>
      <address>
        <city>Szczecin</city>
        <zip>71-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Leczniczo-Rehabilitacyjny Ośrodek Medycyny Rodzinnej</name>
      <address>
        <city>Wrocław</city>
        <zip>53-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eap Sardenya</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cap Apenins - Montigala</name>
      <address>
        <city>Caldes Montbui Canovelles</city>
        <zip>3308140</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cap Canet de Mar</name>
      <address>
        <city>Canet de Mar</city>
        <zip>08360</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cap Centelles</name>
      <address>
        <city>Centelles</city>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Shuang Ho Hospital</name>
      <address>
        <city>New Taipei</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Municipal Wanfang Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mounts Bay Medical Ltd</name>
      <address>
        <city>Hayle</city>
        <zip>TR27 5DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheepcot Medical Centre</name>
      <address>
        <city>Watford</city>
        <zip>WD25 0EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Adam Practice</name>
      <address>
        <city>Wirral</city>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory syncytial virus (RSV)</keyword>
  <keyword>Flu</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

